Is ABBV a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Skyrizi and Rinvoq replacing Humira faster than expected, with revenue (fy 2025, reported) at ~$61.2 billion. The bear case rests on the single largest structural risk is portfolio concentration: Skyrizi and Rinvoq together account for a rapidly growing share of total revenue, meaning any clinical setback, competitive entry in atopic dermatitis (where Regeneron's Dupixent holds a strong position), or government-mandated price cut under the Inflation Reduction Act could materially impair the growth outlook. Analysts covering it are spread from $200.00 to $328.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The single largest structural risk is portfolio concentration: Skyrizi and Rinvoq together account for a rapidly growing share of total revenue, meaning any clinical setback, competitive entry in atopic dermatitis (where Regeneron's Dupixent holds a strong position), or government-mandated price cut under the Inflation Reduction Act could materially impair the growth outlook. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $200.00, -25.0% from the $266.71 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Skyrizi and Rinvoq replacing Humira faster than expected. Skyrizi and Rinvoq generated a combined $25.9 billion in 2025, exceeding AbbVie's own 2027 combined guidance by roughly $500 million two full years ahead of schedule. The most optimistic analyst target on ABBV is $328.00, +23.0% from the $266.71 price. That figure is only reachable if this thesis works close to its best case.

The single largest structural risk is portfolio concentration: Skyrizi and Rinvoq together account for a rapidly growing share of total revenue, meaning any clinical setback, competitive entry in atopic dermatitis (where Regeneron's Dupixent holds a strong position), or government-mandated price cut under the Inflation Reduction Act could materially impair the growth outlook. AbbVie also carries a heavy debt load, reported at roughly $72.9 billion as of the most recent period, a legacy of the Allergan acquisition, constraining financial flexibility if credit markets tighten or a major pipeline bet fails. Ongoing integration of large acquisitions such as the pending Apogee Therapeutics deal introduces execution risk, and the aesthetics segment (Botox Cosmetic, Juvederm) has shown sensitivity to consumer spending cycles and competition from emerging aesthetic treatments. The most pessimistic published target is $200.00, -25.0% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

AbbVie is a North Chicago-based research-driven biopharmaceutical company spun off from Abbott Laboratories in 2013.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Skyrizi and Rinvoq replacing Humira faster than expected) stalling in the reported numbers rather than in the narrative, the risk above (the single largest structural risk is portfolio concentration: Skyrizi and Rinvoq together account for a rapidly growing share of total revenue, meaning any clinical setback, competitive entry in atopic dermatitis (where Regeneron's Dupixent holds a strong position), or government-mandated price cut under the Inflation Reduction Act could materially impair the growth outlook) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

AbbVie is a research-based biopharmaceutical company that discovers and sells medicines for immunology (Skyrizi, Rinvoq, Humira), oncology (Imbruvica, Venclexta), neuroscience (Vraylar, Botox Therapeutic, Ubrelvy), and aesthetics (Botox Cosmetic, Juvederm). It operates globally with roughly 57,000 employees and reported full-year 2025 revenue of approximately $61.2 billion.

Whether ABBV suits a portfolio depends on an investor's goals, time horizon, and existing holdings. The forward P/E near 15.7x and a PEG ratio below 1.0 look relatively modest for a company guiding to double-digit EPS growth in 2026. Key uncertainties include drug pricing policy, portfolio concentration in Skyrizi and Rinvoq, and a large debt load. No single answer fits all investors.

Yes. AbbVie pays a quarterly cash dividend and has raised it for 12 consecutive years. The most recent quarterly dividend is $1.73 per share, for a current annualized payout of roughly $6.92 per share and a yield near 3 percent as of late June 2026. The dividend has grown at roughly 12.5 percent per year since the 2013 Abbott spin-off.